Form 4: Teva Pharmaceutical Director Chen Lichtenstein Granted 14,492 Restricted Share Units

Teva Pharmaceutical Industries Ltd. announced that Director Chen Lichtenstein was granted 14,492 restricted share units, which will vest on June 5, 2026.

Summary

• Director Chen Lichtenstein of Teva Pharmaceutical Industries Ltd. was granted 14,492 Restricted Share Units (RSUs) on June 5, 2025.
• Each RSU represents a contingent right to receive one ordinary share or its cash equivalent, at the discretion of the Human Resources and Compensation Committee.
• These RSUs are scheduled to vest on June 5, 2026.
• Following this transaction, Chen Lichtenstein beneficially owns 14,492 restricted share units directly.

Sentiment

Score: 7

Explanation: The document reports a routine equity compensation grant to a director, which is generally a neutral to slightly positive event as it aligns management interests with shareholders. It does not contain any negative financial or operational news.

Positives

• The grant of restricted share units to a director aligns their interests with long-term shareholder value.
• The acquisition of 14,492 RSUs at a $0 price is a standard compensation component, potentially incentivizing future performance.

Negatives

• No immediate negative implications are apparent from this compensation-related filing.

Risks

• The ultimate value of the restricted share units is contingent on the future market performance of Teva's ordinary shares until the vesting date.

Future Outlook

The vesting of the restricted share units on June 5, 2026, indicates a future date when these units will convert into ordinary shares or their cash equivalent, subject to the terms of the grant.

Management Comments

• The grant of restricted share units is a standard component of executive and director compensation, aligning interests with long-term company performance.

Industry Context

The grant of restricted share units is a common practice in the pharmaceutical industry and broader corporate landscape for executive and director compensation, aiming to incentivize long-term commitment and performance by linking remuneration to share price appreciation.

Comparison to Industry Standards

• The use of Restricted Share Units (RSUs) as a compensation mechanism is a widely adopted practice across global industries, including major pharmaceutical companies like Pfizer, Johnson & Johnson, and Novartis, which frequently utilize equity-based incentives to align executive and director interests with shareholder value.
• A $0 acquisition price for RSUs is standard for compensation grants, reflecting that the value is derived from the underlying stock's future performance rather than an upfront purchase.
• The one-year vesting period (June 5, 2025, to June 5, 2026) for these RSUs is within typical industry ranges, though vesting schedules can vary from immediate to multi-year cliffs or graded vesting, depending on the company's compensation philosophy and specific role.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aims to align their interests with shareholders by incentivizing long-term stock performance.
• Employees: This filing does not directly impact general employees, but it reflects the company's executive compensation practices.

Next Steps

• The restricted share units are expected to vest on June 5, 2026, at which point they will convert into ordinary shares or their cash equivalent.

Key Dates

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, SEC Filing, Restricted Share Units, RSU, Director Compensation, Insider Transaction, Equity Grant, Chen Lichtenstein